Literature DB >> 27981898

The Role of Carbonic Anhydrase in Hepatic Glucose Production.

Ibrahim S Ismail1.   

Abstract

BACKGROUND: Carbonic anhydrase is a ubiquitous zinc metalloenzyme in organisms that primarily catalyzes the reversible hydration of CO2 to HCO3 - and H+. It is involved in many important physiological and pathological conditions such as electrolyte secretion and biosynthetic reaction like gluconeogenesis, lipogenesis and ureagenesis. The enzyme provides HCO3 - as a substrate for pyruvate carboxylase, the first enzyme in hepatic gluconeogenesis. The present review showed that carbonic anhydrase is the main driver of hepatic gluconeogenesis.
METHODS: Google scholar and Medline Embase (inception to 2015) were searched for studies on mechanism of hepatic glucose production, increased hepatic glucose production in diabetes and changes in carbonic anhydrase activity in diabetes and its treatment.
RESULTS: Many studies have linked changes in carbonic anhydrase activity with the development and progression of diabetes mellitus. Carbonic anhydrase has been shown to provide HCO3 - as substrate for the first reaction of hepatic gluconeogenesis which has also been reported to increase significantly in type 2 diabetes. Increase in carbonic anhydrase activity increases the availability of these substrates and in turn increases hepatic glucose production.
CONCLUSION: Carbonic anhydrase can be said to be the key factor responsible for reduction of hepatic glucose production. Thus carbonic anhydrase could serve as a new therapeutic target for reducing hepatic glucose production. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Carbonic anhydrase; gluconeogenesis; lactate; metformin; therapy; type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 27981898     DOI: 10.2174/1573399812666161214122351

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  3 in total

1.  Biochemical Evaluation of Carbonic Anhydrase and Some Antioxidant Markers in Patients with Diabetes Complications.

Authors:  A H Sulaiman; Z I Ghassan; T N Omar
Journal:  Arch Razi Inst       Date:  2022-02-28

2.  The Presence of Serum TgAb Suggests Lower Risks for Glucose and Lipid Metabolic Disorders in Euthyroid General Population From a National Survey.

Authors:  Jinjia Zhang; Yiyang Gao; Yongze Li; Di Teng; Yuanming Xue; Li Yan; Jing Yang; Lihui Yang; Yongli Yao; Jianming Ba; Bing Chen; Jianling Du; Lanjie He; Xiaoyang Lai; Xiaochun Teng; Xiaoguang Shi; Yanbo Li; Haiyi Chi; Eryuan Liao; Chao Liu; Libin Liu; Guijun Qin; Yingfen Qin; Huibiao Quan; Bingyin Shi; Hui Sun; Xulei Tang; Nanwei Tong; Guixia Wang; Jin-An Zhang; Youmin Wang; Zhen Ye; Qiao Zhang; Lihui Zhang; Jun Zhu; Mei Zhu; Weiping Teng; Zhongyan Shan; Jing Li
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-18       Impact factor: 5.555

3.  The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor.

Authors:  Xiaofu Zhang; Ruyi Li; Yingjie Chen; Yuning Dai; Ling Chen; Lei Qin; Xingbo Cheng; Yan Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.